GRACE :: Kidney Cancer

ASCO: Key PD-1 Data in Kidney Cancer!

Share
download as a pdf file Download PDF of this page

I’ve been on a bit of a hiatus in the weeks leading up to ASCO, but I’m hoping to divulge (over the next couple of days) some of the key findings from the meeting.  I’d be remiss to skip over the data related to PD-1 directed therapies.  We saw some large datasets for nivolumab, an agent that gained a lot of momentum in kidney cancer clinical research after some encouraging phase I data.  The larger phase II datasets that were presented at ASCO suggested a slightly lower response rate than the phase I (in the range of 15-25%), and also it seemed as though the delay in cancer growth was a little less profound.  Has this made me less optimistic about PD-1 in RCC?  Not by a longshot.  There were some really interesting datasets presented in which PD-1 was combined with either standard agents for RCC (such as sunitinib or pazopanib), or ipilimumab (another immune modifying agent that we think could complement PD-1).  As a disclaimer, I did participate in this clinical trial, but I can nonetheless provide for you a perspective on the data released at the meeting.  In a nutshell, there are some concerns about toxicity, but the response rates were pretty awesome.  The company leading the study also made a formal announcement of plants to launch a study in the patients with previously untreated kidney cancer, with a randomization to either sunitinib or the combination of nivolumab with ipilimumab.  

Lots of changes ahead.  I’m also really excited about some video interviews I did for GRACE at ASCO .  I pulled my favorite colleagues from around the country for quick 15 minute interviews, getting there thoughts on a whole host of RCC related topics.  I think they did a phenomenal job and I think we’ll be rolling out the videos over the course of the next week or two!  Excited to get your feedback. 


One Response to ASCO: Key PD-1 Data in Kidney Cancer!

  • catdander forum moderator
    catdander forum moderator says:

    I’m so glad you’ve joined us here at Grace, eclipsed only ;) by the high hopes for new treatments for RCC. I’m looking forward to learning more.
    Janine

Leave a Reply

Ask Us, Q&A
Kidney Cancer Expert Content

Archives

Archives

Share
download as a pdf file Download PDF of this page

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share
download as a pdf file Download PDF of this page

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Breast Cancer Blog
Pancreatic Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share
download as a pdf file Download PDF of this page

Subscribe to the GRACEcast Podcast on iTunes

Share
download as a pdf file Download PDF of this page

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share
download as a pdf file Download PDF of this page

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243